GlassScriptPhysician profile
Jordan L Weinstein
NPI 1952353872
$6,239.63
in general payments reported to CMS, 2019-2025
23 companies · $616 in 2025
The $616 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,857 · 2020: $92.88 · 2021: $365 · 2022: $800 · 2023: $776 · 2024: $732 · 2025: $616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,124.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,954.44 | 2019-2024 | Cardiomems |
| Novartis Pharmaceuticals Corporation | $1,374.93 | 2021-2025 | |
| Edwards Lifesciences Corporation | $712.34 | 2019 | |
| Janssen Pharmaceuticals, INC | $519.08 | 2019-2024 | Xarelto |
| Pfizer INC. | $250.22 | 2019-2025 | |
| Heartflow, INC. | $249.91 | 2022-2024 | |
| Amgen INC. | $217.12 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $179.38 | 2022-2025 | Eliquis, Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $147.73 | 2020-2025 | Lifevest |
| Medtronic Vascular, INC. | $142.69 | 2019 | |
| Boston Scientific Corporation | $104.50 | 2019-2023 | Watchman Access System |
| Novo Nordisk INC | $77.56 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.69 | 2023-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $46.05 | 2022-2024 | Farxiga, Brilinta |
| Scpharmaceuticals INC. | $42.98 | 2023-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $27.54 | 2025 | Barostim Neo System |
| Angiodynamics, INC. | $24.47 | 2021 | |
| Merck Sharp & Dohme LLC | $23.10 | 2024 | Verquvo |
| Actelion Pharmaceuticals US, INC. | $20.60 | 2024 | Uptravi, Opsumit |
| Kestra Medical Technology Services, INC. | $20.25 | 2023 | Assure Wcd |
| Amarin Pharma, INC. | $19.24 | 2022 | |
| Sanofi-Aventis U.S. LLC | $16.71 | 2022 | |
| Elutia, INC. | $15.10 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Weinstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.